86 results about "Anti-apoptosis" patented technology

The invention provides a composition for promoting hair regeneration after chemotherapy as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: modifying the surface of a gold nanocage with polydopamine, loading the modified gold nanocage on an exosome, complexing magnesium ions and zinc ions to prepare a modified exosome, preparing a nano drug-loaded liposome from curcumin, resveratrol and epigallocatechin gallate, mixing the nano drug-loaded liposome with the modified exosome to prepare a multi-layer liposome, and preparing the multi-layer liposome from the nano drug-loaded liposome. And mixing with a penetration enhancer, and adding into a temperature-sensitive hydrogel system to prepare the composition for promoting hair regeneration after chemotherapy. The composition for promoting hair regeneration after chemotherapy has a good transdermal absorption promoting effect, can slowly release drugs, promotes hair follicles to be converted from a resting stage to a growing stage under the synergistic effect of the drugs, regulates and controls multiple pathways (such as anti-apoptosis, angiogenesis promotion and anti-inflammation) at the same time, is matched with a complex pathological mechanism of hair regeneration after chemotherapy, and can promote hair regeneration after chemotherapy. Wide application prospects are realized.

The invention relates to a stem cell pretreatment technology in the field of biomedicine, which is characterized in that stem cells are pretreated in a specific parameter window (10-80mu g / mL, 5-60min and 36-38 DEG C) by establishing an ozone concentration-time-temperature cooperative control model, so that the anti-apoptosis ability, homing efficiency and paracrine function of the stem cells are remarkably enhanced. The method breaks through the technical bottleneck of low survival rate of traditional stem cell transplantation, and avoids the carcinogenic risk of gene modification. The application covers the three fields of myocardial repair, liver regeneration and nerve injury, and the special culture medium and the kit developed in a matched manner realize standardized operation. The survival rate of the pretreated stem cells after transplantation is increased by more than two times, the VEGF secretion amount is increased by 150%, and a safe and efficient new treatment strategy is provided for clinic.

The invention provides a method for improving the success rate of single cell culture under external stimulation, belongs to the field of cell culture, and can solve the problem that the contradiction between a Raman spectrum signal and the survival rate can be formed by improving laser energy in the existing single cell culture. The method comprises the following steps: preparing a working solution containing an allogenic material; pretreating an experimental strain by using a culture medium containing the allogenic material to obtain a cell suspension; introducing the cell suspension into chambers of a micro-fluidic chip, and adjusting the cell suspension until each chamber contains at most one cell; in the presence of the allogenic material, culturing the single cell; wherein the allogenic substance is selected from one or more of an antioxidant substance, an anti-radiation substance, an anti-apoptosis substance and a repair promoting substance. According to the method, the exogenous material is added into the culture medium, and the micro-fluidic chip with a plurality of chambers is adopted for single cell culture, so that the survival rate and the clone formation rate of the single cells after Raman sorting can be remarkably improved, meanwhile, the advantage of low background interference is kept, and the survival rate of the single cells is improved.

Use of a BCL2 inhibitor in the preparation of a drug or medical instrument for treating giant congenital melanocytic nevi (GCMN). The use of the BCL2 inhibitor in GCMN has been validated to exert a therapeutic effect by means of reversing anti-apoptotic response of GCMN and inducing apoptosis of GCMN. In addition, good killing effects have been achieved in both primary GCMN cells from multiple patients and animal experiments, indicating that the BCL2 inhibitor has a strong and specific killing effect on giant nevus cells while exerting minimal impact on other normal cells, thereby achieving precise therapeutic and killing effects to address the predicament of the lack of effective treatment methods for GCMN.

An apoptosis-promoting solid dispersion comprises a Bcl-2 family protein inhibiting compound of Formula A as defined herein dispersed in a solid matrix comprising (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A method for preparing such a solid dispersion comprises subjecting a compound of Formula A, a water-soluble polymeric carrier, and a surfactant to high temperature treatment to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound substantially non-crystalline form dispersed therein. The solid dispersion is suitable for oral administration to a subject in need thereof to treat a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, such as a cancer or an immune or autoimmune disease.

The invention provides a hydrogel sustained-release material loaded with melatonin and mecobalamin as well as a preparation method and application of the hydrogel sustained-release material, and belongs to the technical field of medicine synthesis. According to the invention, HyStem-HP and thiolated gelatin are taken as hydrogel carriers, melatonin and mecobalamin are loaded, and the hydrogel sustained-release material loaded with melatonin and mecobalamin is prepared. A three-dimensional network structure is constructed through a physical or chemical cross-linking technology, synergistic slow release of melatonin and mecobalamin is achieved, the drug action time is prolonged, frequent drug administration requirements are reduced, oxidation resistance and apoptosis resistance of melatonin are combined with the nerve repairing function of mecobalamin, photoreceptor cell degeneration is doubly delayed, and the melatonin-mecobalamin-melatonin-mecobalamin-melatonin-mecobalamin-melatonin-mecobalamin-melatonin-mecobalamin- meanwhile, high-concentration accumulation of the medicine at the retinopathy part can be realized through local injection of the hydrogel, and the medicine is continuously released for several weeks, so that the blood retina barrier limitation is broken through.

The invention discloses wheat malt seedling functional dietary fibers as well as a preparation method and application of the wheat malt seedling functional dietary fibers. The soluble dietary fiber and the insoluble dietary fiber of the wheat malt seedlings are extracted by adopting a wall breaking-extraction mode of synergy of biological enzyme and free radicals. The wheat malt seedling soluble dietary fibers can prolong the life of caenorhabditis elegans in an oxidative stress state, improve the antioxidant enzyme activity and improve the anti-apoptosis capability; the intestinal flora of the obese C57BL / 6J mouse induced by the high-fat feed is regulated; the wheat malt seedling insoluble dietary fiber has better binding water capacity, water-holding capacity and cholesterol and sodium cholate adsorption capacity, and can be used as a functional food additive for improving the texture and nutritional characteristics of food; and the wheat malt seedlings can also be used for assisting in reducing serum cholesterol level, preventing arteriosclerosis, promoting defecation, preventing constipation, colorectal cancer and the like in the field of health medical treatment, so that high-quality reutilization of the wheat malt seedlings is realized.

Novel populations of canine derived stem cells useful for treatment across allogeneic barriers. The stem cells can be of mesenchymal lineage optimized to possess enhanced proliferative activity in vitro and in vivo without significant loss of therapeutic functionality. Said therapeutic activities include angiogenesis, stimulation of growth factor production, antifibrotic effects, neurogenesis, immune modulation, and antiapoptotic effects.

The invention belongs to the field of biological medicine, and particularly relates to an application of rose natural extracellular vesicles in preparation of cardiovascular protection products, the rose extracellular vesicles are extracted through a classical ultracentrifugation method, biological characteristics of the rose extracellular vesicles are identified and confirmed through a transmission electron microscope (a tea tray type nano vesicle structure) and a nano-particle tracking analyzer (80-150 nm, 1.8 E + 11 Particle / mL) in a combined mode, and the application of the rose extracellular vesicles in preparation of cardiovascular protection products is achieved. After research, it is found that when the rose extracellular vesicles are applied to cardiovascular products, the rose extracellular vesicles have the effects of (a) promoting endothelial cell proliferation; (b) inhibiting endothelial cell apoptosis; and (c) a function of enhancing oxidation resistance. The invention verifies the application of the rose natural extracellular vesicles, and the experimental research finds that the rose extracellular vesicles as a natural active ingredient have a remarkable effect in synchronous triple regulation (proliferation promotion-apoptosis resistance-oxidation resistance) of human umbilical vein endothelial cells (HUVEC), and can be used for preparing the rose natural extracellular vesicles. And a new way is provided for developing non-engineering cardiovascular protection products with high safety performance.

The invention relates to an agent containing zingerone, an active plant compound derived from ginger that is easy to use, non-toxic, antioxidant, and anti-apoptotic, for the treatment of diabetes-related male reproductive damage.

An apoptosis-promoting solid dispersion comprises a Bcl-2 family protein inhibiting compound of Formula A as defined herein dispersed in a solid matrix comprising (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A method for preparing such a solid dispersion comprises subjecting a compound of Formula A, a water-soluble polymeric carrier, and a surfactant to high temperature treatment to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound substantially non-crystalline form dispersed therein. The solid dispersion is suitable for oral administration to a subject in need thereof to treat a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, such as a cancer or an immune or autoimmune disease.

The invention discloses a method for preparing schizophyllum commune polysaccharide through high-pressure homogenization and application of the schizophyllum commune polysaccharide, and belongs to the technical field of food and medical treatment. On the basis of a traditional water extraction and alcohol precipitation process, the molecular weight and viscosity of schizophyllum commune fermentation liquor polysaccharide are remarkably reduced through a high-pressure homogenization technology, the schizophyllum commune fermentation liquor polysaccharide is smoother in morphology, and meanwhile a triple-helix structure is maintained; the physical properties of the polysaccharide treated by the method are optimized, and the immunoregulation, anti-apoptosis and anti-oxidative damage activity are also remarkably enhanced. Furthermore, the polysaccharide-selenium nanoparticle compound is prepared from the polysaccharide, sodium selenite and L-ascorbic acid through a mild one-step oxidation-reduction method, the water solubility, biocompatibility and bioavailability of the polysaccharide can be effectively improved through the compound, and the polysaccharide-selenium nanoparticle compound shows more excellent apoptosis resistance and oxidation resistance in a model experiment.

The present invention provides a method for preparing mesenchymal stem cell exosomes and its application. N-acetylcysteine and quercetin are added to the culture medium used for culturing MSC cells, so as to stimulate MSC to produce exosomes with anti-aging and anti-apoptosis effects. Moreover, by gradually reducing the oxygen partial pressure for culturing, the exosomes produced by stimulating MSC further have anti-aging effects. And after the cells are induced and cultured with N-acetylcysteine and quercetin, it can inhibit the adverse effects such as acute oxidative stress, decreased proliferation ability and unstable quality produced under hypoxic conditions without damaging the activity of cell and exosome-related components. This method shows good anti-aging and anti-apoptosis effects in vitro, providing a new idea for the future application of exosomes in the treatment of senile diseases.

This invention relates to a detection kit and preparation method for enhancing the detection efficacy of autoimmune encephalitis (CBA) antibodies. The kit comprises genetically engineered 293T cells stably integrating and co-expressing the eIF2α S52A mutant and HSP70, and transiently transfected with CBA-associated antigens. The preparation method includes constructing a co-expression vector, establishing a stable transfection cell line, stress preconditioning treatment, antigen transfection, and kit assembly. A method for assessing antibody affinity maturation using this kit is also provided. By synergistically modifying detection cells at three levels—translational regulation, protein folding, and anti-apoptosis—the invention significantly increases antigen expression, reduces apoptosis, and improves detection sensitivity and specificity. Furthermore, it integrates antibody affinity assessment into CBA detection for the first time, providing auxiliary information for clinical staging.

The invention is applicable to the technical field of biological medicine, and provides a metformin-engineered umbilical cord mesenchymal stem cell and a preparation method and application thereof, and the preparation method comprises the following steps: taking fresh umbilical cord tissue, cleaning, cutting into small blocks, performing adherent culture, and performing fusion passage when the cell grows to 80%; and co-incubating the P5-generation human umbilical cord mesenchymal stem cells and metformin, and centrifugally collecting the cells after pancreatin digestion to obtain the metformin-engineered umbilical cord mesenchymal stem cells. The concentration of the metformin is 500 [mu] mol / L. Metformin is used for pretreating human umbilical cord mesenchymal stem cells to construct Met-MSC with metabolism enhancement and function optimization characteristics, so that the Met-MSC has stronger anti-apoptosis, anti-oxidation, angiogenesis promotion and immunoregulation capabilities, a safe, simple, convenient and convertible new cell treatment strategy is provided, and the application bottleneck of traditional MSC treatment in diabetic foot ulcer is broken through.

The application belongs to the technical field of medicine, and discloses a pentacyclic triterpene derivative, a preparation method and medical application of the pentacyclic triterpene derivative, which uses alpha-hederin or oleanolic acid as raw material, and utilizes esterification reaction or amidation reaction aiming at the carboxyl of C-28 to prepare the pentacyclic triterpene derivative. The pentacyclic triterpene derivative prepared by the application has the effects of anti-inflammation, anti-oxidation and anti-apoptosis, and the synthesis method is simple, the raw material is cheap and easy to obtain, and is suitable for industrial application.

The invention relates to the technical field of biological medicine, in particular to application of zinc-ginsenoside coordination nano-enzyme in treatment of diabetic nephropathy. The Zn (at) Gs-Re nano-enzyme provided by the invention not only enhances the stability and biological activity of ginsenoside Re, but also endows the ginsenoside Re with novel similar SOD / CAT enzyme activity, realizes multiple synergistic effects of resisting oxidation, resisting inflammation, resisting apoptosis, protecting mitochondria and improving renal functions, and shows remarkable superiority in the aspect of treating diabetic nephropathy and related complications.

The application relates to an anti-apoptosis baculovirus expression vector, which realizes a broad-spectrum anti-apoptosis effect by expressing siRNA targeting a Sf-caspase-1 and Tn-caspase-1 common sequence of Spodoptera frugiperda and Trichoplusia ni insect cells through the vector. The baculovirus vector contains a specific DNA sequence, the DNA sequence contains an siRNA sequence targeting the Sf-caspase-1 and Tn-caspase-1 common sequence transcribed by an RNA polymerase III promoter; the recombinant virus of the vector can express double-stranded small RNA in a host cell, silences the caspase-1 encoded by the host cell through an RNA interference pathway, thereby inhibiting the apoptosis of the host cell, and significantly improving the expression level of an exogenous protein. The application can be used for industrialized production of protein preparations and vaccines.

The present disclosure is directed to a combination therapy comprising an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein and an inhibitor of an anti-apoptotic Bcl-2 family protein, and methods of use thereof.

The present disclosure relates to eukaryotic cell lines with a stable integrated loss-of-function or attenuation-of-function mutation in each of the Bax and Bak genes. Also provided are methods of producing such cell lines. This disclosure also relates to compositions and cell cultures comprising such cell lines, as well as methods of producing a product, such as a recombinant polypeptide or viral vector, using said cells, compositions and cell cultures.

The invention discloses a composition with effects of delaying gingival atrophy and repairing oral mucosa and a preparation method thereof. The composition comprises recombinant III-type collagen, elastin, a pseudo-ginseng root extract, a salvia officinalis extract and a gallnut extract, all the components are compounded according to specific parts by mass, and the composition has good synergistic repair, anti-inflammatory, anti-oxidation and anti-apoptosis effects. The composition can be applied to oral care products such as toothpaste, can effectively inhibit inflammatory response, relieve oxidative stress and reduce the apoptosis rate, so that gingival atrophy is delayed, oral mucosa repair is promoted, and the composition has a wide application prospect.

The invention relates to the technical field of radiation protection, in particular to a dietary nutrition supplement capable of relieving radon internal irradiation damage and having a protective effect and a preparation method thereof, and the dietary nutrition supplement comprises the following raw materials: compound vitamins, nicotinamide, selenium-enriched yeast and propolis. Animal experiments prove that after the dietary nutrition supplement is taken, the dietary nutrition supplement not only is beneficial to relieving oxidative damage and apoptosis resistance caused by radon irradiation, inhibiting autophagy and relieving damage of radon daughters to lung cells, but also does not generate toxic and side effects, and achieves the purposes of safety and effectiveness.

The invention belongs to the technical field of biology, and particularly relates to an embryo biopsy culture solution, an embryo biopsy method and application of the embryo biopsy culture solution. A polypeptide growth factor; a signal path modulator; wherein the signal channel regulator comprises an ROCK signal channel inhibitor and / or an MLCK signal channel inhibitor. According to the biopsy culture solution disclosed by the invention, all the components can efficiently and synergistically act on an embryo biopsy microenvironment through careful screening and optimized combination and collocation; further, the physiological environment of the embryo can be accurately simulated, the integrity and stability of the morphological structure of the embryo are maintained, the operation damage of embryo biopsy is remarkably reduced, key nutrition support and anti-apoptosis protection are provided, and the development potential and transplantation conception rate of the embryo are maintained; the invention effectively solves the core problems of poor embryo survival ability, low re-cavity rate, impaired developmental potential, low transplantation conception rate and the like caused by embryo biopsy in the prior art, provides a standardized, efficient, stable and safe special culture solution for early embryo biopsy operation of mammals, and is highly compatible with a genetics detection technology. The application prospect is wide.

The invention provides a serum-free embryo cutting biopsy culture solution and application thereof, and belongs to the technical field of embryo cutting biopsy. The serum-free embryo cutting biopsy culture solution comprises a basic culture medium component, antioxidant components such as vitamins, a protein growth factor component, a small molecule inhibitor component and other molecular compound components. According to the biopsy culture solution disclosed by the invention, through careful screening and optimized combination and collocation, all the components can have an efficient synergistic effect, key nutrition support and anti-apoptosis protection are provided, the operation injury of embryo biopsy is effectively reduced, and the efficient development potential and transplantation conception rate of embryos are maintained. The serum-free cutting biopsy culture solution has clear chemical components, eliminates instability caused by serum factors, and solves the problem of long-term lack of efficient, stable and standardized serum-free cutting biopsy culture solutions in the field of embryo cutting biopsy. The method has a wide application prospect in the fields of livestock embryo genome selective breeding and embryo cutting biopsy.

The invention discloses an engineered exosome for targeted improvement of an ovarian function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The engineered exosome is prepared by performing membrane fusion on an exosome from human umbilical cord mesenchymal stem cells overexpressing VEGFA (vascular endothelial growth factor A) genes and an FSH (follicle stimulating hormone) beta subunit derived peptide modified liposome. The exosome has the functions of promoting angiogenesis and resisting apoptosis of VEGFA (vascular endothelial growth factor A) and the ovarian targeting capability of the FSH beta peptide fragment, can accurately act on ovarian granular cells, and effectively improves the ovarian microenvironment and follicle development. The preparation method comprises the following steps: constructing VEGFA overexpression engineering cells, extracting exosomes, synthesizing targeted lipidosome, performing ultrasonic induction fusion and the like. The engineered exosome provided by the invention has the advantages of strong targeting, definite curative effect, high uniformity, good safety and the like, and provides a new strategy for cell-free treatment of ovarian function decline and related reproductive disorders.

Mastocytosis is a rare and heterogeneous disorder marked by the abnormal accumulation of mast cells (MCs) in various tissues. Tyrosine kinase inhibitors have shown limited efficacy, suggesting that additional molecular mechanisms are involved. The inventors showed the unexpected expression of AXL in neoplastic mast cells from patients with various forms of mastocytosis. This is particularly noteworthy as AXL expression had never been investigated in mast cells, whether neoplastic or normal. The study demonstrated the role of AXL, particularly in cooperation with KIT D816V to drive mast cell proliferation and resistance to therapies. In an embodiment, the AXL inhibitor bemcentinib (R428) is used in combination with the TKI midostaurin (PKC 412). The AXL-L197M identified in the ASM patient is pro-proliferative, and induces resistance to death in CD34-derived mast cells and in Ba-f3. Furthermore, the results also suggest that a combination of AXL inhibitors and BCL-2 inhibitors may be appropriate for the treatment of mastocytosis. In conclusion, AXL inhibitors can be thus suitable for the treatment of mastocytosis.

The invention discloses a method for large-scale acquisition of mesenchymal stem cell exosomes with high expression of IL-10 and application of the mesenchymal stem cell exosomes, and relates to the technical field of umbilical cord mesenchymal stem cell exosomes. The method comprises the following steps: carrying out cross culture on umbilical cord mesenchymal stem cells by adopting complete culture and hunger culture, and collecting a solution discharged from a cell factory when the hunger culture is finished each time, so as to obtain an exosome stock solution; and filtering the exosome stock solution to remove impurities, so as to obtain the mesenchymal stem cell exosome with high expression of IL-10. According to the method, proliferation of the umbilical cord mesenchymal stem cells can be effectively inhibited through alternate culture of the starvation culture medium and the complete culture medium, exosome secretion is stimulated, and high-yield, high-efficiency and stable exosome production is achieved. The mesenchymal stem cell exosome with high expression of IL-10 is applied to clinical treatment of HFpEF, has an anti-apoptosis protection effect on myocardial cells, and effectively promotes angiogenesis.

The invention relates to an adiponectin receptor regulating peptide as well as a composition, a product and application thereof. The amino acid sequence of the adiponectin receptor regulating peptide is as follows: (a), any one of the amino acid sequences as shown in SEQ ID NO. 1 to 30, SEQ ID NO. 32, SEQ ID NO. 35 to 39, SEQ ID NO. 42, SEQ ID NO. 46, SEQ ID NO. 47, SEQ ID NO. 49 and SEQ ID NO. 50; or (b) any one of amino acid sequences which are obtained by modifying the N end and / or the C end of the adiponectin receptor regulating peptide limited by (a) and have the same or similar functions. The adiponectin receptor regulating peptide provided by the invention can activate an adiponectin receptor / AMPK signal channel and promote hair growth, has multiple effects of oxidation resistance, inflammation resistance and apoptosis resistance, can improve skin aging, and has wide application prospects in the fields of medicines, foods and cosmetics.